Obicetrapib

Overview

Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein ( CETP ) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB , Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).

Application

Products | Products > Disease Areas > Atherosclerosis | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Cardiovascular Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > CETP | Products > Signaling Pathways > Apolipoprotein | Products > Signaling Pathways > LPL Receptor | Products > Signaling Pathways > LDLR

Product Information

• Catalog No.: HY-18778
• CAS No.: 866399-87-3
• Molecular Formula: C32H31F9N4O5
• Molecular Weight: 722.60
• Purity: 99.93%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (3.46 mM); Clear solution
• Availability: In-stock

Source

Original product source